Accessibility Menu
Pure Bioscience logo

Pure Bioscience

(OTC) PURE

Current Price$0.07
Market Cap$8.52M
Since IPO (1996)-100%
5 Year-87%
1 Year-31%
1 Month+2%

Pure Bioscience Financials at a Glance

Market Cap

$8.52M

Revenue (TTM)

$2.41M

Net Income (TTM)

-$2.16M

EPS (TTM)

-$0.02

P/E Ratio

-3.39

Dividend

$0.00

Beta (Volatility)

0.22 (Low)

Price

$0.07

Volume

22,864

Open

$0.06

Previous Close

$0.07

Daily Range

$0.06 - $0.07

52-Week Range

$0.04 - $0.14

Estimated Earnings Date

Jun 16, 2026

PURE News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Pure Bioscience

Industry

Household Products

Employees

12

CEO

Robert F. Bartlett

Headquarters

El Cajon, CA 91730, US

PURE Financials

Key Financial Metrics (TTM)

Gross Margin

541%

Operating Margin

-82%

Net Income Margin

-90%

Return on Equity

0%

Return on Capital

87%

Return on Assets

-3%

Earnings Yield

-29.50%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$8.52M

Shares Outstanding

130.02M

Volume

22.86K

Avg. Volume

39.08K

Financials (TTM)

Gross Profit

$1.30M

Operating Income

-$2.27M

EBITDA

-$2.10M

Operating Cash Flow

-$2.02B

Capital Expenditure

$0.00

Free Cash Flow

-$2.02B

Cash & ST Invst.

$334.00M

Total Debt

$523.60K

Pure Bioscience Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$444.00K

+13.6%

Gross Profit

$238.00K

+4.8%

Gross Margin

53.60%

N/A

Market Cap

$8.52M

N/A

Market Cap/Employee

$774.20K

N/A

Employees

11

N/A

Net Income

-$785.00K

+1.6%

EBITDA

-$683.00K

+6.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$198.00K

-2.0%

Total Debt

$6.15M

+54.6%

Accounts Receivable

$252.00K

+40.0%

Inventory

$244.00K

+225.3%

Long Term Debt

$4.01M

+0.8%

Short Term Debt

$2.14M

N/A

Return on Assets

-2.74%

N/A

Return on Invested Capital

87.43%

N/A

Free Cash Flow

-$606.00K

-11.4%

Operating Cash Flow

-$606.00K

-11.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
DQWSDSwiss, Inc.
$0.04+0.00%
EXDWExceed World, Inc.
$0.29+0.00%
HERBYaSheng Group
$0.03+0.00%
CAWWCCA Industries, Inc.
$0.48-4.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$14.80+0.05%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$13.59+0.04%
TQQQProShares Trust - ProShares UltraPro Qqq
$77.52+0.02%
SMCISuper Micro Computer
$30.46-0.05%

Questions About PURE

What is the current price of Pure Bioscience?

Pure Bioscience is trading at $0.07 per share.

What is the 52-week range for Pure Bioscience?

Over the past 52 weeks, Pure Bioscience has traded between $0.04 and $0.14.

How much debt does Pure Bioscience have?

As of the most recent reporting period, Pure Bioscience reported total debt of $6.15M.

How much cash does Pure Bioscience have on hand?

Pure Bioscience reported $273.00K in cash and cash equivalents in its most recent financial results.

What is Pure Bioscience’s dividend yield?

Pure Bioscience does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.